Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05877547 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 381
- Enrollment target
NCT05877547 is a Phase 2 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 381 participants.
The verdict
NCT05877547, a Phase 2 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 381 participants
- Enrollment target
Study Summary
The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Researchers will also learn about the safety and benefit of efinopegdutide and how well people tolerate the medicine. The main goal of the study is to compare how many people taking efinopegdutide or placebo stop showing evidence of NASH without liver scarring getting worse.
Interventions
- DRUG Placebo
- DRUG Semaglutide
- DRUG Efinopegdutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 381 participants |
| Start Date | 2023-06-23 |
| Est. Completion | 2025-12-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05877547
The ClinicalTrials.gov registry entry for NCT05877547 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 381 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05877547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05877547 about?
NCT05877547 is a clinical study titled "A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)". The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Researchers will also learn about the safety and benefit of efinopegdutide and how well people tolerate the medicine. The main goal of the study is to comp...
What is the current status of trial NCT05877547?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 381 participants. The study started on 2023-06-23. Estimated completion is 2025-12-29.
What interventions are being tested in trial NCT05877547?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG), Efinopegdutide (DRUG).
Who is sponsoring clinical trial NCT05877547?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.